NCT02313883View on ClinicalTrials.gov

A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions
Periodontitis
Interventions
DRUG

PerioSept(r)

Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties

Trial Locations (4)

19104

University of Pennsylvania, Philadelphia

48109

University of Michigan School of Dentistry, Ann Arbor

77063

Perio Health Professionals, Houston

92835

Regenerative solutions, Fullerton

Sponsors
All Listed Sponsors
lead

Geistlich Pharma AG

INDUSTRY

NCT02313883 - A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis | Biotech Hunter | Biotech Hunter